What’s new on emerging resistant Candida species

Cortegiani, Andrea; Misseri, Giovanni; Chowdhary, Anuradha

doi:10.1007/s00134-018-5363-x

Cited by 43 publications

(40 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[7,9] Although current treatment guidelines include FCZ as one of the most common options for the treatment of candidiasis, the azole resistance of multiple strains limits its clinical use. [8,[10][11][12] For some Candida species, notably C. glabrata, C. krusei and C. auris, the increasing rate of azole resistance is prevalent, [7,8,11,13,14] emphasizing the importance of finding alternatives for the treatment of these infections. The mode of action of azole-containing antifungal agents involves the inhibition of 14α-lanosterol demethylase (CYP51), a key enzyme in the biosynthesis of ergosterol (resulting in its depletion).…”

Section: Introductionmentioning

confidence: 99%

Cationic Ru^II Cyclopentadienyl Complexes with Antifungal Activity against Several Candida Species

et al. 2020

View full text Add to dashboard Cite

Fungal infections, including those caused by antifungal-resistant Candida, are a very challenging health problem worldwide. Whereas different ruthenium complexes were previously studied for their anti-Candida potential, Ru-cyclopentadienyl complexes were overlooked. Here, we report an antifungal activity assessment of three Ru-cyclopentadienyl complexes with some insights into their potential mode of action. Among these complexes, only the cationic species [Ru-ACN] + and [Ru-ATZ] + displayed a significant antifungal activity against different Candida strains, notably against the ones that did not respond to one of the most currently used antifungal drugs fluconazole (FCZ). However, no apparent activity was observed for the neutral species, RuÀ Cl, thus indicating the important role of the cationic backbone of these complexes in their biological activity. We suggest that reactive oxygen species (ROS) generation might be involved in the mechanism of action of these complexes as, unlike neutral RuÀ Cl, [Ru-ACN] + and [Ru-ATZ] + could generate intracellular concentration-dependent ROS. We also observed a correlation between the ruthenium cellular uptake, ROS generation and fungal growth inhibitory activity of the compounds. Furthermore, docking simulations showed that the CYP51 enzyme can form more energetically favorable complexes with [Ru-ATZ] + than fluconazole (FCZ); this suggests that CYP51 inhibition could also be considered as a potential mode of action.

show abstract

Section: Introductionmentioning

confidence: 99%

Cationic Ru^II Cyclopentadienyl Complexes with Antifungal Activity against Several Candida Species

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Candida species particularly Candida albicans remains the most 1,2 common cause of supercial and deep fungal infections worldwide . But an increase in the prevalence of Non albicans Candida (NAC) during the last few decades is a matter of concern for various laboratories, as NAC show less susceptibility to commonly used [3][4][5] antifungal agents particularly azoles ie uconazole .…”

Section: Introductionmentioning

confidence: 99%

A Study on Identification and Speciation of Medically Important Candida Species Isolated From Various Clinical Samples by Using Hicrome Candida.

Jogender

Kulshrestha

Rishi

2020

ijsr

View full text Add to dashboard Cite

Candida albicans remains the most frequently isolated species, but an increase in the prevalence of Non-albicans candida is a matter of concern for 1-3 various laboratories, as NAC show less susceptibility to antifungal agents particularly azoles . Routinely used conventional methods are cumbersome and time consuming. Hence the present study aimed at species identication of candida isolated from various clinical specimens and also to evaluate the usefulness of HiCrome Candida differential agar as compared to routine conventional method for speciation of candida. A total of 51 non repetitive clinical isolates of Candida were obtained from various clinical samples. Candida albicans was the major species accounting for 23 (45.10%) of the total isolates. Non albicans Candida constituted 17 (33.33%) of C. tropicalis, 9 (17.64%) of C. krusei and 2 (3.92%) of C. parasilosis. 49 Candida species which were correctly identied by HiCrome Candida agar except 2 species of C.parasilosis (identied by conventional method) which were identied as C. glabrata by Hicrome Candida agar.

show abstract

“…Candida species are considered the most frequent fungi encountered in hospital settings accounting for more than 400,000 cases of bloodstream infections each year, making them the third to fourth most common cause of invasive fungal infections worldwide [1,[4][5][6]. Candida albicans is recognized as the main causative pathogen of candidiasis [1].…”

Section: Introductionmentioning

confidence: 99%

Attack, Defend and Persist: How the Fungal Pathogen Candida auris was Able to Emerge Globally in Healthcare Environments

Jong

Hagen

2019

Mycopathologia

View full text Add to dashboard Cite

Within a decade after its first description, the multidrug-resistant yeast Candida auris has emerged globally as a nosocomial pathogen causing difficult to control outbreaks. This, together with the alarmingly high mortality rate of up to 66% associated with C. auris candidemia, calls for a better understanding of its virulence traits and routes of transmission. Unlike other clinically relevant Candida species, C. auris seems to have the unique ability to be easily transmitted between patients. Although initially thought to express fewer virulence traits than Candida albicans, recent genomic insights suggest C. auris to possess these traits to a much more similar extent. This review highlights the virulence traits C. auris expresses to attack the host, defend itself against antimicrobial agents and to persist within the healthcare environment.

show abstract

What’s new on emerging resistant Candida species

Cited by 43 publications

References 22 publications

Cationic Ru^II Cyclopentadienyl Complexes with Antifungal Activity against Several Candida Species

Cationic Ru^II Cyclopentadienyl Complexes with Antifungal Activity against Several Candida Species

A Study on Identification and Speciation of Medically Important Candida Species Isolated From Various Clinical Samples by Using Hicrome Candida.

Attack, Defend and Persist: How the Fungal Pathogen Candida auris was Able to Emerge Globally in Healthcare Environments

Contact Info

Product

Resources

About

What’s new on emerging resistant Candida species

Cited by 43 publications

References 22 publications

Cationic RuII Cyclopentadienyl Complexes with Antifungal Activity against Several Candida Species

Cationic RuII Cyclopentadienyl Complexes with Antifungal Activity against Several Candida Species

A Study on Identification and Speciation of Medically Important Candida Species Isolated From Various Clinical Samples by Using Hicrome Candida.

Attack, Defend and Persist: How the Fungal Pathogen Candida auris was Able to Emerge Globally in Healthcare Environments

Contact Info

Product

Resources

About

Cationic Ru^II Cyclopentadienyl Complexes with Antifungal Activity against Several Candida Species

Cationic Ru^II Cyclopentadienyl Complexes with Antifungal Activity against Several Candida Species